Feb 1, 2022 · Recent mechanism studies demonstrate that the disulfiram−copper complex, bis (diethyldithiocarbamate)-copper (CuET, also denoted as Cu (DDC) 2, Cu (DTC) 2, and Cu (DEDC) 2 in different studies), is the decisive metabolite for …

Dec 6, 2017 · Our nationwide epidemiological study reveals that patients who continuously used disulfiram have a lower risk of death from cancer compared to those who stopped using the drug at their diagnosis.

Nov 9, 2023 · In an effort to search for the vulnerability of ESCC, we applied a high-throughput drug-screening strategy and found that CuET, a copper chelation product of disulfiram, had a strong synergy effect with the JMJD3/UTX inhibitor GSK J4 in treating ESCC in vitro and in vivo.

Here we highlight the potential for repurposing disulfiram (also known by the trade name Antabuse), an old alcohol-aversion drug that has been shown to be effective against diverse cancer types...

Feb 1, 2022 · Recent mechanism studies demonstrate that the disulfiram−copper complex, bis (diethyldithiocarbamate)-copper (CuET, also denoted as Cu (DDC) 2, Cu (DTC) 2, and Cu (DEDC) 2 in different studies), is the decisive metabolite for tumor suppressing effects [ …

Dec 1, 2022 · Satisfactorily, compared to direct oral feeding of DSF and CuGlu, intravenous Cu-LCP/DSF NP treatment engendered a more powerful inhibition of tumor growth at a lower dosage, indicating the better bioavailability of this nano-formulation.

Jul 4, 2014 · The oral administration of DS/copper gluconate (CuGlu) was compared with i.v administration of Lipo-DS plus oral administration of CuGlu. In comparison with the control group, both Lipo-DS/CuGlu and Lipo-DS significantly inhibited tumor growth but Lipo-DS/CuGlu demonstrated highest anticancer efficacy (Fig. 5A and 5B ).

Herein, a new copper (II) gluconate complex, namely [Cu (DPQ) (Gluc)]·2H 2 O (CuGluc, DPQ = pyrazino [2,3-f] [1,10]phenanthroline), with good water-solubility and high anticancer activity was synthesized by using D-gluconic acid (Gluc-2H) as an auxiliary ligand.

Sep 28, 2022 · After how long over the period of tumor confirmation, authors started to oral administration of DSF/CuGlu? Since the trial phase, Glioblastoma patients were administered with 80mg/1.5 mg of DSF and Cu (https://clinicaltrials.gov/ct2/show/NCT03034135).

Sep 28, 2022 · Researchers have demonstrated that DSF interacted with copper (Cu) to form the metabolite CuET, which acts as a shuttle for Cu to cross the cell membrane and release Cu under oxidative conditions; thus, targeting cancer via inhibiting the activity of p97-dependent proteasomes via nuclear protein localization protein 4 (NPL4) [19, 20].